866-997-4948 (US-Canada Toll Free)

Dialysis Partnering 2007-2013

Published By :

Current Partnering

Published Date : 2013-07-01

Category :

Dialysis

No. of Pages : 100

Product Synopsis


The Dialysis Partnering 2007-2013 provides understanding and access to the dialysis partnering deals and agreements entered into by the worlds leading healthcare companies.

The report provides an analysis of dialysis partnering deals. The majority of deals are discovery or development stage whereby the licensee obtains a right or an option right to license the licensors dialysis technology. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.

Understanding the flexibility of a prospective partners negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered contract documents provide this insight where press releases do not.

This data driven report contains over 30 links to online copies of actual dialysis deals and contract documents as submitted to the Securities Exchange Commission by companies and their partners, where available. Contract documents provide the answers to numerous questions about a prospective partners flexibility on a wide range of important issues, many of which will have a significant impact on each partys ability to derive value from the deal.

The initial chapters of this report provide an orientation of dialysis partnering trends.

Chapter 1 provides an introduction to the report, whilst 

Chapter 2 provides an overview of the trends in dialysis partnering since 2007, including a summary of deals by industry sector, stage of development, deal type, and technology type. Numerous tables provide outline financial trends.

Chapter 3 provides an overview of the leading dialysis deals since 2007. Deals are listed by headline value, signed by bigpharma, most active bigpharma. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.

Chapter 4 provides a comprehensive directory of dialysis partnering deals signed and announced since 2007. The chapter is organized by company A-Z, stage of development at signing, deal type (collaborative R&D, co-promotion, licensing etc), and technology type. Each deal title links via Weblink to an online version of the deal record, and where available the contract document, providing easy access to each contract document on demand.

In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of dialysis technologies and products.

Report scope

Dialysis Partnering 2007-2013 is intended to provide the reader with an in-depth understanding and access to dialysis trends and structure of deals entered into by leading companies worldwide.

This data driven report includes:

  • Trends in dialysis dealmaking in the biopharma industry since 2007 
  • Access to summary headline, upfront, milestone and royalty data 
  • The leading dialysis deals by value since 2007 

In Dialysis Partnering 2007-2013, the available deals are listed by:

  • Headline value 
  • Upfront payment value 
  • Royalty rate value 
  • Company A-Z 
  • Industry sector 
  • Stage of development at signing 
  • Deal component type 
  • Technology type 

Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

Table Of Content

Table of Content

Executive Summary

Chapter 1 Introduction

Chapter 2 Trends in dialysis partnering
2.1. Introduction
2.2. Dialysis partnering over the years
2.3. Bigpharma dialysis dealmaking activity
2.4. Dialysis partnering by deal type
2.5. Dialysis partnering industry sector
2.6. Dialysis partnering by stage of development
2.7. Dialysis partnering by technology type
2.8. Disclosed financial deal terms for dialysis partnering
2.8.1 Dialysis headline values
2.8.2 Dialysis upfront payments
2.8.3 Dialysis milestone payments
2.8.4 Dialysis royalty rates

Chapter 3 Leading dialysis deals
3.1. Introduction
3.2. Top dialysis deals by value
3.3. Top dialysis deals involving bigpharma

Chapter 4 Dealmaking directory
4.1. Introduction
4.2. Company A-Z
4.3. By deal type
Asset purchase
Bigpharma outlicensing
Co-development
Collaborative R&D
Co-market
Contract service
Co-promotion
CRADA
Cross-licensing
Development
Distribution
Equity purchase
Evaluation
Grant
Joint venture
Licensing
Manufacturing
Marketing
Option
Promotion
Research
Settlement
Spin out
Sub-license
Supply
Termination
4.4. By industry sector
Academic
Bigpharma
Biotech
Drug delivery
Medical device
Diagnostic
Generic pharma
Government
Non-profit
Pharmaceutical
Research tools
Services
Specialty pharma
4.5. By stage of development
Discovery
Pre-clinical
Phase I
Phase II
Phase III
Registration
Marketed
4.6. By technology type
Analysis
Animal models
Assays
Bioinformatics
Biological compounds
Biomarkers
Biomaterials
Cell culture
Cell therapy
Clinical testing
Diagnostic - companion
Devices
Diagnostics
Discovery tools
DNA probes
Drug delivery
Enabling technology
Epigenetics
Equipment
Facilities
Gene therapy
Genomics
Imaging
Industrial chemicals
In vitro models
Monoclonal antibodies
Nanotechnology
Oligonucleotide
Peptides
Personalised medicine
Processes
Proteomics
Radio/Chemo-therapy
Recombinant DNA
Research services
Research supplies
RNA therapeutics
Screening
Small molecules
Stem cells
Vaccines

Chapter 5 Partnering resource center
5.1. Online partnering
5.2. Partnering events
5.3. Further reading on dealmaking

Appendices

Appendix 1 Deal type definitions
About Wildwood Ventures
Current Partnering
Current Agreements
Recent titles from CurrentPartnering
Order Form Reports

List of Tables

NA

List of Figures


Figure 1: Dialysis partnering since 2007 
Figure 2: Bigpharma top 50 dialysis deals 2007 to 2011 
Figure 3: Bigpharma dialysis deal frequency 2007 to 2011 
Figure 4: Dialysis partnering by deal type since 2007 
Figure 5: Dialysis partnering by industry sector since 2007 
Figure 6: Dialysis partnering by stage of development since 2007 
Figure 7: Dialysis partnering by technology type since 2007 
Figure 8: Dialysis deals with a headline value 
Figure 9: Dialysis deals with upfront payment values 
Figure 10: Dialysis deals with milestone payments 
Figure 11: Dialysis deals with royalty rates, % 
Figure 12: Top dialysis deals by value since 2007 
Figure 13: Top dialysis deals signed by bigpharma value since 2007 
Figure 14: Online partnering resources 
Figure 15: Forthcoming partnering events 
Figure 16: Deal type definitions

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *

Upcoming Reports

  • Point Of Sale (POS) Terminals Market - Global Industry Size, Market Share, Trends, Analysis And Forecasts 2012 - 2018

    By - Transparency

    Point of sale terminal is a computerized process for replacing cash register. This system is capable of recording and keeping track of customer orders, processing credit and debit cards, connecting to other systems, and managing the inventory. Point of sale terminal has a personal computer as its core which is provided with a specific application program and I/O devices for particular environment. This system is used in various industries including entertainment, restaurants, lodging, and museums requiring point of sale like service desk.   Some of the drivers of...

  • Hydro-Pumped Storage Plants Market - Global Industry Analysis, Size, Share, Trends, Analysis, Growth and Forecast, 2014 - 2020

    By - Transparency

    The increasing demand for energy storage systems and emergence ancillary services is one of the main market drivers for pumped storage hydro in the future. Hydro-pumped storage plants system is a form of hydroelectric energy storage used by the power industry for the purposes of peak shaving and load balancing. In hydro-pumped storage plants, water flows from a lower elevation reservoir to another reservoir at a higher elevation where it is stored. During times of peak demand this stored water is utilized to run turbines whereas the low cost off-peak electric power is used to pump back...

  • Nucleic Acid Aptamers (Diagnostics and Therapeutics) Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2012 - 2018

    By - Transparency

    Nucleic acid aptamers are species of nucleic acid that are engineered in in vitro selection or SELEX i.e. systematic evolution of ligands by exponential enrichment. Aptamers bind different molecular targets such as proteins, nucleic acids, cells, organisms and other molecules and assist in molecular recognition of certain characters that fight antibodies. Aptamers have remarkable advantage over antibodies as they can be easily produced through chemical synthesis and can be engineered in vitro. Aptamers are commonly developed as ligands offering molecular recognition properties that...